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Shujaul Haqa, John Madaraa, Margot Boigona, Donald C. Haasa, David L. Fischmanc

Abstract

odds of in-hospital mortality. A high LCR at presentation might indicate impending clinical deterioration and the need for IMV.

Background: Systemic inflammation elicited by a cytokine storm is
considered a hallmark of coronavirus disease 2019 (COVID-19). This
study aims to assess the validity and clinical utility of the lymphocyte-to-C-reactive protein (CRP) ratio (LCR), typically used for gastric carcinoma prognostication, versus the neutrophil-to-lymphocyte
ratio (NLR) for predicting in-hospital outcomes in COVID-19.
Methods: A retrospective cohort study was performed to determine
the association of LCR and NLR with the need for invasive mechanical ventilation (IMV), dialysis, upgrade to an intensive care unit (ICU)
and mortality. Independent t-test and multivariate logistic regression
analysis were performed to calculate mean differences and adjusted
odds ratios (aORs) with its 95% confidence interval (CI), respectively.
Results: The mean age for NLR patients was 63.6 versus 61.6, and
for LCR groups, it was 62.6 versus 63.7 years, respectively. The baseline comorbidities across all groups were comparable except that the
higher LCR group had female predominance. The mean NLR was
significantly higher for patients who died during hospitalization (19
vs. 7, P ≤ 0.001) and those requiring IMV (12 vs. 7, P = 0.01). Compared to alive patients, a significantly lower mean LCR was observed
in patients who did not survive hospitalization (1,011 vs. 632, P =
0.04). For patients with a higher NLR (> 10), the unadjusted odds of
mortality (odds ratios (ORs) 11.0, 3.6 - 33.0, P < 0.0001) and need for
IMV (OR 3.3, 95% CI 1.4 - 7.7, P = 0.008) were significantly higher
compared to patients with lower NLR. By contrast, for patients with
lower LCR (< 100), the odds of in-hospital all-cause mortality were
significantly higher compared to patients with a higher LCR (OR 0.2,
0.06 - 0.47, P = 0.001). The aORs controlled for baseline comorbidities and medications mirrored the overall results, indicating a genuinely significant correlation between these biomarkers and outcomes.
Conclusions: A high NLR and decreased LCR value predict higher
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Introduction
The coronavirus disease 2019 (COVID-19) is a global pandemic caused by the novel severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). By binding to the angiotensinconverting enzyme 2 (ACE2) receptor, the S1 subset of the
surface spike protein elicits the production of angiotensin 1.
The ACE then converts angiotensin 1 to angiotensin 2, which
in turn binds to the angiotensin receptor, upregulating the
levels of endothelin-1 (ET-1). This results in a widespread
inflammatory response with the release of pro-inflammatory
cytokines and interleukins [1, 2]. The large-scale unregulated
production of interleukins, particularly interleukin-6 (IL-6),
stimulates several downstream pathways, increasing the production of acute-phase reactants like C-reactive protein (CRP),
and increases mobilization of neutrophils [3]. This, along with
stress-induced neutrophilia, likely explains the relative lymphopenia seen in severe manifestations of the SARS-CoV-2
infection [4-6].
Several studies have sought to demonstrate the clinical
utility and feasibility of the neutrophil-to-lymphocyte ratio
(NLR) in predicting COVID-19 outcomes [6]. A high NLR
value at admission has been proposed as suggestive of COVID-19, while confirmatory tests are pending and a rising NLR
has been shown to be associated with worse clinical outcomes
in severe COVID-19. While the NLR is well studied, a similar
biomarker ratio, the lymphocyte-to-CRP ratio (LCR), has, so
far, not been utilized. Typically, the LCR is used as a prognostic marker for several types of cancers, including colon and
gastric carcinomas [7-10]. The rationale behind this is that the
LCR serves as a good surrogate of the complex host-tumor
immunological interactions that result in a systemic inflammatory process, which is believed to contribute towards the
pathogenesis and progression of these carcinomas [11]. Since
COVID-19 also precipitates a systemic inflammatory response,
it follows that the LCR may also be a good proxy marker in
this disease process and may carry prognostic value.
The present study aims to shed light on whether LCR and
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NLR can, in fact, be used as reliable predictors for adverse
outcomes. We further analyzed their predictive capability by
subdividing adverse complications and correlating the LCR
and NLR ratios observed in each instance.

fever, freedom from symptoms, substantial clinical or radiological improvement for at least 1 day.

Materials and Methods

Continuous variables were presented as mean and standard
deviations (SD); categorical variables were reported in percentages and proportions. A Chi-square (χ2) test was used for
comparison of categorical data; Fisher’s exact test was only
adopted if the expected count in more than 20% cells was less
than 5. To quantify the association between the dichotomous
categorical variables, an unadjusted odds ratio (OR) was obtained using the Cochran-Mantel-Haenszel method. To explore
the risk factors and gauge the impact of potential effect modifiers (covariates) on our endpoints (in-hospital death, need for
an upgrade, ventilators and dialysis) binomial and multinomial
logistic regression models were applied as appropriate. The
differences in the baseline comorbidities (DM, HTN, CAD,
CKD) and medication use (HCQ, tocilizumab, remdesivir, AC
and steroids) were accounted for to obtain an adjusted odds
ratio (aOR) for all outcomes. The Hosmer-Lemeshow (HL)
goodness-of-fit test was used to predict the fitness of logistic regression models for applicability to categorical data. For
normally and abnormally distributed continuous data, an independent sample t-test and Mann-Whitney U test were utilized,
respectively. A one-way analysis of variance (ANOVA) was
used to compare differences in the mean of continuous variables for multiple in-hospital complications. A two-sided α of
less than 0.05 was considered statistically significant corroborating inference from a 95% confidence interval (CI). Statistical analyses were performed using the SPSS software (version
25).

Study design and participants
This retrospective cohort study included consecutive adult
inpatients (≥ 18 years old) from Abington Hospital-Jefferson
Health, PA, USA. All patients had a confirmed diagnosis of
COVID-19 between March 1, 2020 and May 10, 2020. This
study was conducted in compliance with the ethical standards
of the responsible institution on human subjects as well as with
the Helsinki Declaration. The study was approved by the Institutional Review Board (IRB).
Patient and public involvement
The study was retrospective in design, data was obtained by
chart review and there were no direct patient interactions. No
patient was involved in the design, recruitment and conduct of
the study. The development of research question and outcome
measures were influenced by common inpatient outcomes for
hospitalized patients and the results of this study will not be
directly disseminated to study participants.
Data collection
Clinical, demographic, laboratory, treatment, and outcome
data were extracted from electronic medical records (Sunrise)
using a standardized data collection form. All authors contributed to data retrieval and an independent author adjudicated
any difference in interpretation between the data extractors.
SARS-CoV-2 was detected in respiratory specimens (throat
swabs) by next-generation sequencing or real-time qualitative
polymerase chain reaction (RT-qPCR) methods. The laboratory values, cutoff variables and methods for laboratory confirmation of SARS-CoV-2 infection were standardized. Data
regarding baseline comorbidities included a history of diabetes mellitus (DM), hypertension (HTN), chronic kidney disease (CKD) and coronary artery disease (CAD). In-hospital
medications used included hydroxychloroquine (HCQ), tocilizumab, steroids and anticoagulation (AC). Routine blood work
included coagulation profile, complete blood count, serum biochemical tests (renal function, CRP, D-dimer, lactate dehydrogenase (LDH), myocardial enzymes (troponin T (TnT)) and
serum ferritin. Chest radiographs or computed tomography
(CT) scans were also done for most inpatients where clinically
indicated. Acute cardiac injury was diagnosed if serum levels
of cardiac biomarkers (TnT) were above the 99th percentile
upper reference limit in conjunction with new abnormalities
on the electrocardiography (EKG) and transthoracic echocardiography (TTE). The criteria for discharge were absence of
416

Statistical analysis

Results
Demographics and baseline characteristics
A total of 176 consecutive patients with a confirmed diagnosis of COVID-19 were included in our study. Patients were
divided into two comparison groups: low NLR (< 10) versus
high NLR (> 11), and low LCR (< 100) and high LCR (> 101).
The mean age for NLR patients was 63.6 versus 61.6 and for
LCR groups, it was 62.6 versus 63.7 years. The baseline comorbidities across all groups were comparable except that
the higher LCR group had female predominance. The proportions of underlying comorbidities between low and high NLR
groups included DM (83.9% vs. 16.1%), HTN (86.9% vs.
13.1%), CAD (93.1% vs. 6.1%), CKD (87.1% vs. 12.9%), and
chronic obstructive pulmonary disease (COPD) (91.7% vs.
8.3%) respectively. These percentages for low and high LCR
groups were: DM (21.1% vs. 78.9%), HTN (23.0% vs. 80.0%),
CAD (19.4% vs. 80.6%), CKD (25% vs. 75%), and COPD
(16.7% vs. 83.3%), respectively. Patients in both NLR and
LCR groups had similar proportions of medication use (HCQ,
tocilizumab, AC, steroids) across both groups (P value ≥ 0.05)
(Fig. 1, Table 1).
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AC versus no AC (1,633 ± 3,094 vs. 783 ± 1,661, P = 0.18)
were not significantly different (Fig. 2).
In outcomes

Figure 1. Baseline characteristics of the included populations.

Mean differences in NLR and LCR
In interventions
The mean difference in the levels of NLR and LCR between
patients on definitive COVID-19 therapy compared to those
not receiving therapy were mostly identical across its respective groups with few exceptions. On day 1 of presentation, the
mean NLR for patients receiving HCQ versus no HCQ were 8
± 9 versus 5 ± 4 (P = 0.15), tocilizumab versus no tocilizumab
8 ± 6 versus 7 ± 9 (P = 0.84), AC versus no AC 10 ± 16 versus
7 ± 5 (P = 0.19) and steroids versus no steroids 6 ± 5 versus
8 ± 9 (P = 0.51), respectively. Similarly, there was no significant difference in the post-treatment mean values of NLR in
patients who received HCQ versus no HCQ (9 ± 11 vs. 5 ± 3,
P = 0.28), tocilizumab versus no tocilizumab (10 ± 14 vs. 9 ±
9, P = 0.74), and steroids versus no steroids (11 ± 14 vs. 8 ±
9, P = 0.16) respectively. The mean NLR for patients on AC
was significantly higher compared to the no AC group (15 ±
17 vs. 7 ± 7, P = 0.02). The mean LCR values closely followed
the overall trend of mean NLR ratios. The mean LCR in HCQ
versus no HCQ was 563 ± 1,632 versus 6,820 ± 30,751 (P =
0.28), tocilizumab versus no tocilizumab 681 ± 1,238 versus
1,851 ± 14,221 (P = 0.64), AC versus no AC (1,117 ± 2,882 vs.
1,759 ± 1,427, P = 0.80) and steroids versus no steroids (766 ±
1,247 vs. 1,816 ± 1,414,122, P = 0.69) respectively. On day 7,
the mean LCR for the patients on tocilizumab was significantly
higher than those not on tocilizumab (2,718 ± 3,418 vs. 461 ±
1,034, P = 0.00). The mean LCR for patients on HCQ versus
no HCQ (918 ± 2,085 vs. 1,654 ± 1,224, P = 0.36), steroids
versus no steroids (1,183 ± 208 vs. 893 ± 2,047, P = 0.50) and

Mean differences in NLR and LCR for hard clinical outcomes
such as in-hospital mortality and resource allocation were also
calculated. The mean NLR and LCR differences on day 1 of
admission were not significantly different between patients requiring an upgrade (10 ± 13 vs. 6 ± 5, P = 0.06; 4,010 vs. 493,
P = 0.25), ventilator support (9 ± 12 vs. 6 ± 5, P = 0.05; 3,675
vs. 515, P = 0.26) and dialysis (11 ± 8 vs. 7 ± 8, P = 0.20; 712
vs. 1,688, P = 0.82) compared to corresponding patients not requiring an upgrade, ventilator and dialysis. Similarly, the mean
difference in NLR and LCR in patients surviving compared to
patients who died on presentation was identical (7 ± 9 vs. 9 ±
6, P = 0.42; 1,784 vs. 474, P = 0.67), respectively. On day 7,
higher means of NLR were associated with a higher requirement for invasive mechanical ventilation (IMV) (12 ± 10 vs.
7 ± 10, P = 0.01) and increased mortality (19 ± 13 vs. 7 ± 9,
P ≤ 0.0001). Higher mean LCR was associated with a higher
need for an upgrade (1,784 vs. 452, P = 0.001) and IMV (1,592
vs. 489, P = 0.01). The mean LCR for surviving patients was
higher compared to non-surviving patients (1,011 vs. 632, P =
0.04). (Fig. 2; Supplementary Materials 1, 2, www.jocmr.org).
In complications
In terms of in-hospital complications, patients with new-onset
atrial fibrillation (AF) in conjunction with sepsis had the highest mean of NLR (27.65 ± 37.48), while patients with heart
failure and AF had the highest mean value of LCR (8,177.46
± 11,468.12). The detailed rates and mean values are given in
Supplementary Materials 3, 4 (www. jocmr.org).
ORs of outcomes
On presentation, the unadjusted OR for in-hospital mortality
(OR 1.6, 0.5 - 5.5, P = 0.63), need for upgrade to intensive
care unit (ICU) (OR 1.7, 0.7 - 4.1, P = 0.30), and requirement
for IMV (OR 1.5, 0.6 - 3.5, P = 0.46) and dialysis (OR 2.5,
0.6 - 10.3, P = 0.39) were not significantly different between
patients with high NLR (> 11) and those with low NLR. By
contrast, the unadjusted odds for LCR served as reliable predictors for primary endpoints at presentation. High LCR (>
101) was associated with a significantly higher odds of IMV
and upgrade (OR 2.5, 1.3 - 5.0, P = 0.01; OR 2.9, 1.47 - 6.1, P
= 0.004), respectively. The odds of need for dialysis (OR 1.8,
0.4 - 7.1, P = 0.63) and mortality (OR 0.71, 0.3 - 1.8, P = 0.62)
were identical between patients with high NLR and low NLR
on day 1 (Tables 2, 3, Fig. 3).
On day 7 of hospitalization, high NLR was associated
with higher odds of in-hospital mortality (OR 11.0, 3.6 - 33.0,
P < 0.0001) and a higher requirement for IMV (OR 3.3, 1.4 7.7, P = 0.008). There was no significant difference in the need
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Table 1. Baseline Characteristics of the Included Population Across Comparison Groups for Which the Pooled Estimate Were Adjusted
NLR < 10

NLR > 11

Significance

LCR < 10

LCR > 11

Significance

63.6 years

61.6 years

P = 0.71

62.6 years

63.7 years

P = 0.65

  Men

66 (80.50%)

16 (19.50%)

P = 0.167

23 (27.70%)

60 (72.30%)

P = 0.04

  Women

75 (88.20%)

10 (11.80%)

13 (14.90%)

74 (85.10%)

  No

92 (85.20%)

16 (14.80%)

23 (21.10%)

86 (78.90%)

  Yes

49 (83.10%)

10 (16.90%)

13 (21.30%)

48 (78.70%)

  No

48 (80.00%)

12 (20.00%)

14 (23.30%)

46 (76.70%)

  Yes

93 (86.90%)

14 (13.10%)

22 (20.00%)

88 (80.00%)

  No

114 (82.60%)

24 (17.40%)

30 (21.60%)

109 (78.40%)

  Yes

27 (93.10%)

2 (6.90%)

6 (19.40%)

25 (80.60%)

  No

114 (83.80%)

22 (16.20%)

28 (20.30%)

110 (79.70%)

  Yes

27 (87.10%)

4 (12.90%)

8 (25.00%)

24 (75.00%)

  No

119 (83.20%)

24 (16.80%)

32 (21.90%)

114 (78.10%)

  Yes

22 (91.70%)

2 (8.30%)

4 (16.70%)

20 (83.30%)

  No

27 (87.10%)

4 (12.90%)

8 (27.60%)

21 (72.40%)

  Yes

114 (83.80%)

22 (16.20%)

28 (19.90%)

113 (80.10%)

  No

117 (84.80%)

21 (15.20%)

28 (20.30%)

110 (79.70%)

  Yes

24 (82.80%)

5 (17.20%)

8 (25.00%)

24 (75.00%)

  No

115 (83.30%)

23 (16.70%)

32 (22.90%)

108 (77.10%)

  Yes

26 (89.70%)

3 (10.30%)

4 (13.30%)

26 (86.70%)

  No

115 (85.80%)

19 (14.20%)

25 (18.40%)

111 (81.60%)

  Yes

26 (78.80%)

7 (21.20%)

11 (32.40%)

23 (67.60%)

Age
Sex

DM
P = 0.716

P = 0.974

HTN
P = 0.237

P = 0.611

CAD
P = 0.16

P = 0.784

CKD
P = 0.65

P = 0.557

COPD
P = 0.29

P = 0.56

HCQ
P = 0.65

P = 0.354

TM
P = 0.78

P = 0.557

SD
P = 0.39

P = 0.247

AC
P = 0.318

P = 0.075

DM: diabetes mellitus; HTN: hypertension; CKD: chronic kidney disease; CAD: coronary artery disease; COPD: chronic obstructive pulmonary disease; HCQ: hydroxychloroquine; TM: tocilizumab; SD: steroid; AC: anticoagulation.

for upgrade to ICU (OR 2.4, 1.0 - 5.4, P = 0.06) and dialysis
between the two groups (OR 1.2, 0.2 - 6.1, P = 0.81). Patients
in the low LCR group had significantly higher odds of mortality (OR 0.2, 0.06 - 0.47, P = 0.001), while there was no significant difference in the need for an upgrade (P = 0.16), IMV (P
= 0.21) and dialysis (0.70) between low and high LCR groups.
A multivariate regression model was used to adjust the
observed odds ratios for baseline comorbidities and medications, including DM, HTN, CKD, CAD, use of AC at home,
HCQ, tocilizumab, steroids and therapeutic AC during a hospital stay. The adjusted odds values were consistent with unad418

justed ORs indicating no influence of covariates as shown in
Tables 2 and 3.

Discussion
Our study reveals that a lower LCR and a high NLR could
serve as predictive markers for in-hospital complications and
mortality in patients with COVID-19. Compared to NLR, high
LCR on presentation accurately predicts the in-hospital need
for IMV and an upgrade to the ICU. During hospitalization,
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Figure 2. Mean NLR and LCR values at day 1 and day 7 of hospitalization across different interventions and outcomes. NLR: neutrophil-tolymphocyte ratio; LCR: lymphocyte-to-C-reactive protein ratio.

while an elevated NLR was also associated with higher odds of
ICU upgrade and ventilatory support, a similar correlation was
not seen with the LCR values. Even after completion of offlabel therapy for COVID-19 (HCQ, tocilizumab), a high NLR
and low LCR were associated with significantly higher odds of
in-hospital mortality. Based on our findings, we advocate for
the use of LCR as a reliable predictor of the risk of in-hospital
complications at presentation, while both high NLR and low
LCR are useful prognostic markers for overall mortality risk.
To the best of our knowledge, this is the first study among patients with COVID-19 identifying the potential role of LCR in
predicting the outcomes of COVID-19.
Both NLR and LCR serve to highlight a relative lymphopenia compared to normal or elevated neutrophil counts and
raised CRP levels, respectively. Based on previous studies, it
is believed that COVID-19-related widespread inflammation
results in immune dysregulation and apoptotic loss of lymphocytes [12]. The coronavirus has also been demonstrated
in circulating lymphocytes, causing a direct cytotoxic mediated destruction [8, 13]. Lymphopenia, by these mechanisms,
as well as stress-mediated neutrophilia, leads to a high NLR.
However, the LCR may be more sensitive in capturing the early part of the inflammatory cascade as CRP levels have been
shown to rise earlier than either neutrophilia or lymphopenia is
seen. Thus, a low LCR and a high NLR, which both represent
systemic inflammation, albeit at different time frames, can be
regarded as independent markers of in-hospital complications

and mortality [6].
A previous meta-analysis by Lagunas-Rangel et al, on six
studies, concluded that a rise in the NLR and decline in LCR
might correlate with the severity of COVID-19 [13]. While
this study has duly evaluated the prognostic ability of LCR and
NLR for adverse post-infective outcomes, it was vastly underpowered to stratify its results based on specific outcomes. By
contrast, our study has determined that adjusted odds of LCR
could be a reliable marker in the prediction for the need for
high-level care, ventilator support and in-hospital all-cause
mortality. Additionally, our study demonstrated that the incidence of in-hospital complications is higher with a high LCR
at presentation, while the mortality risk correlates with a high
NLR and low LCR during hospitalization.
It is also important to note that, while high NLR is known
to correlate with the severity of COVID-19-related complications, its utility might be limited in certain situations. For
instance, patients on high-dose steroids can have a falsely elevated NLR due to the demargination of neutrophils and ensuing neutrophilia. This is vividly demonstrated in our study,
with a mean NLR on steroids of 11.3 ± 14, significantly higher
than that of patients not on steroid therapy (8.2 ± 9). Similarly,
NLR could falsely be suppressed in immunocompromised patients with neutropenia either due to the chemotherapy or bone
marrow infiltration by the primary malignancy. LCR, in these
situations, can serve as a reliable marker to predict the severity
of the disease as this value is unaffected by the aforementioned
confounders. Nonetheless, both LCR and NLR values should
not be used as absolute indicators and require interpretation in
the clinical context.
Early predictability of in-hospital complications can help
in timely and effective allocation of available resources. Physicians can, therefore, adopt aggressive therapeutic measures
in patients with initial high LCR, rising NLR and decreasing
LCR. In the setting of a pandemic, with finite healthcare resources to allocate, it is essential for providers to have robust
and validated tools to guide where best these resources can
be deployed. We believe that NLR and LCR when used in the
appropriate clinical setting can play just such a role for healthcare teams by assisting early triage and guiding prognosis in
COVID-19 patients.
Limitations
The findings of our study should be interpreted in light of its
limitations. Due to the retrospective non-randomized nature of
the study, a causal relationship could not be ascertained. Although the overall findings were adjusted for covariates, including baseline comorbidities and medications, the impact of
unmeasured confounders such as initiation of several complementary therapies at the treating physician’s discretion, could
not be determined. Based on our clinical experience, the average duration of any therapy for COVID-19 was less than 7
days; therefore, we chose to use day 1 and day 7 laboratory
values. However, given the variable frequency of laboratory
specimen collection, it is not possible for us to ascertain if
these truly represented pre- and post-treatment values accurately in all cases. Moreover, by excluding patients still in the

Articles © The authors | Journal compilation © J Clin Med Res and Elmer Press Inc™ | www.jocmr.org

419

LCR: A Predictor of Adverse Outcomes in COVID-19

J Clin Med Res. 2020;12(7):415-422

Table 2. ORs of Outcomes in NLR Groups on Day 1 and Day 7 of Treatment
Outcomes
Vent
No vent
Upgrade
No upgrade
Dialysis
No dialysis
Died
Alive
Outcomes
Vent
No vent
Upgrade
No upgrade
Dialysis
No dialysis
Died
Alive

N

NLR < 10

NLR > 11

57
110
53
114
10
157
18
149

46 (81%)
95 (86%)
42 (79%)
99 (87%)
7 (70%)
134 (85%)
14 (78%)
127 (85%)

11 (19%)
15 (14%)
11 (21%)
15 (13%)
3 (30%)
23 (15%)
4 (22%)
22 (15%)

N

NLR < 10

NLR > 11

55
80
50
85
8
127
18
117

36 (66%)
69 (86%)
34 (68%)
71 (84%)
6 (75%)
99 (78%)
12 (67%)
99 (85%)

19 (34%)
11 (14%)
16 (32%)
14 (16%)
2 (25%)
28 (22%)
6 (33%)
18 (15%)

Day 1
Unadjusted odds (P value)

aOR (P value)

OR 1.5 (0.6 - 3.5, P = 0.46)

aOR 1.5 (0.6 - 3.7, P = 0.33)

OR 1.7 (0.7 - 4.1, P = 0.30)

aOR 1.7 (0.7 - 4.1, P = 0.24)

OR 2.5 (0.6 - 10.3, P = 0.39)

aOR 2.5 (0.5 - 11.2, P = 0.25)

OR 1.6 (0.5 - 5.5, P = 0.63)

aOR 1.9 (0.5 - 6.7, P = 0.30)

Day 7
Unadjusted odds (P value)

aOR (P value)

OR 3.3 (1.4 - 7.7, P = 0.008)

aOR 3.1 (1.2 - 8.4, P = 0.024)

OR 2.4 (1.0 - 5.4, P = 0.06)

aOR 2.3 (0.9 - 6.1, P = 0.08)

OR 1.2 (0.2 - 6.1, P = 0.81)

aOR 0.7 (0.1 - 5.7, P = 0.73)

OR 11.0 (3.6 - 33.0, P < 0.0001)

aOR 11.1 (3.11 - 39.1, P < 0.0001)

aOR: adjusted odds ratio; OR: odds ratio; NLR: neutrophil-to-lymphocyte ratio.

Table 3. ORs of Outcomes in LCR Groups on Day 1 and Day 7 of Treatment
N

LCR < 100

LCR > 101

Day 1
Unadjusted odds (P value)

Vent

60

17 (28%)

43 (72%)

OR 2.5 (1.3 - 5.0, P = 0.01)

aOR 2.5 (1.3 - 5.0, P = 0.009)

No vent

110

55 (50%)

55 (50%)

Upgrade

55

14 (26%)

41 (75%)

OR 2.9 (1.47 - 6.1, P = 0.004)

aOR 3.1 (1.5 - 6.3, P = 0.003)

No upgrade

115

58 (50%)

57 (50%)

Dialysis

10

3 (30%)

7 (70%)

OR 1.8 (0.4 - 7.1, P = 0.63)

aOR 1.8 (0.4 - 8.0, P = 0.44)

No dialysis

160

69 (43%)

91 (57%)

Died

20

10 (50%)

10 (50%)

OR 0.71 (0.3 - 1.8, P = 0.62)

aOR 0.8 (0.3 - 2.0, P = 0.60)

Alive

150

62 (41%)

88 (58%)

Outcomes

aOR (P value)

N

LCR < 100

LCR > 101

Day 7
Unadjusted odds (P value)

Vent

56

12 (21%)

44 (78%)

OR 1.8 (0.8 - 4.0, P = 0.21)

aOR 1.06 (0.43 - 2.64, P = 0.89)

No vent

76

25 (33%)

51 (68%)

Upgrade

50

10 (20%)

40 (80%)

OR 2.0 (0.9 - 5.0, P = 0.16)

aOR 1.16 (0.46 - 2.96, P = 0.74)

No upgrade

82

27 (33%)

55 (67%)

Dialysis

7

1 (14%)

6 (86%)

OR 2.4 (0.3 - 21.0, P = 0.70)

aOR 3.7 (0.2 - 55.6, P = 0.34)

No dialysis

125

36 (29%)

89 (71%)

Died

19

12 (63%)

7 (37%)

OR 0.2 (0.06 - 0.47, P = 0.001)

aOR 0.1 (0.01 - 0.30, P < 0.0001)

Alive

113

25 (22%)

88 (78%)

Outcomes

aOR (P value)

aOR: adjusted odds ratio; OR: odds ratio; LCR: lymphocyte-to-C-reactive protein ratio.
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to-lymphocyte ratio.
Suppl 4. Mean Value of LCR on Day 1 and Day 7 of Hospitalization Across Different Complications. LCR: lymphocyteto-C-reactive protein ratio.

Acknowledgments
None to declare.

Financial Disclosure
None to declare.

Conflict of Interest
None to declare.

Informed Consent
Not applicable.

Author Contributions
Figure 3. Forest plots of unadjusted odds ratio of outcomes across
NLR and LCR groups. NLR: neutrophil-to-lymphocyte ratio; LCR: lymphocyte-to-C-reactive protein ratio.

hospital, the case fatality ratio in our study cannot reflect the
true mortality of COVID-19. Lastly, the interpretation of our
findings might be limited by the sample size. However, by adjusting the adult patients with confirmed disease, we believe
that our population is the best representative of the real-world
cohort.
Conclusions
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A high LCR at presentation appears to predict an increased
need for IMV and intensive care. A high NLR and low LCR,
after COVID-19 therapy, predict higher odds of mortality.
Large-scale studies are needed to validate our findings.
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